CCCC logo

C4 THERAPEUTICS INC

CCCCNASDAQ
πŸ† #3093 by market capEarnings Feb 25US Equity
$2.48β€”
Last available close Β· quote unavailable
πŸ””
Track CCCC
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ–Ό 10.1%
14dβ–Ό 19.6%
30dβ–Ό 18.7%
ytdβ–² 29.8%
1yβ–² 1.8%
🏦Market Cap
$326M
Small Cap
πŸ“ˆRevenue Growth (YoY)
1.0%
Slowing
πŸ“ŠGross Margin
94.4%
High
πŸ’΅FCF Margin
-247.1%
Thin
βš–οΈP/S Ratio
10.1x
Elevated
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
β€”
52-Week Range
$1.69 – $5.17
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
131.3M
Next Earnings
2027-02-25

Fundamentals Snapshot

Annual Revenue
$36M
Last Q Revenue
$8M
P/E Ratio
-3.4
P/S Ratio
10.1x
EPS (TTM)
$-0.67
Dividend Yield
0.00%
Dilution (1yr)
+65.4%
CCCC logo

C4 THERAPEUTICS INC

CCCC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$36Mβ–² +1.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.8%β–Ό βˆ’22.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$104Mβ–Ό βˆ’12.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$99Mβ–² +52.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
116.8Mβ–² +65.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15Mβ–² +$25M YoY
StockOtter Β· stockotter.space

About C4 THERAPEUTICS INC

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

Zacks Investment ResearchΒ·4d ago

Is C4 Therapeutics (CCCC) Outperforming Other Medical Stocks This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and CareDx (CDNA) have performed compared to their sector so far this year.

Zacks Investment ResearchΒ·17d ago

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.44 per share a year ago.

GlobeNewsWireΒ·17d ago

C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab; Progr

GlobeNewsWireΒ·19d ago

C4 Therapeutics to Participate in Upcoming November Investor Conferences

WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announce

GlobeNewsWireΒ·20d ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that

Zacks Investment ResearchΒ·24d ago

C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

C4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.